retatrutide after Phase III study demonstrates 30% weight loss 1 month Reta update :

Reddys Laboratories - Generic version likely under Obeda Zydus Lifesciences - Reusable pen delivery innovation Sun Pharmaceutical Industries - Preparing to enter the segment Natco Pharma + Eris Lifesciences - Manufacturing + commercialization partnership #Pharma #Healthcare #GLP1 #DiabetesCare #Biotech #IndianPharma #HealthcareInnovation #PharmaIndustry #Semaglutide GLP-1 Patent Expiry Boosts Indian Pharma GLP-1 Patent Expiry: A Big Opportunity for Indian Pharma The race has already begun

Germany Focuses on Private Sector Treatment Access Demand for obesity GLP-1 treatment in Germany is projected to grow at a CAGR of 19.6%, constrained by statutory health insurance exclusions for anti-obesity medications that limit public reimbursement

Current UK practice, as reflected in guidance from the Centre for Perioperative Care (CPOC) and the Joint British Diabetes Societies (JBDS), generally supports continuing GLP-1 receptor agonists perioperatively for most patients, with appropriate risk assessment and precautions

Every 10 units equals exactly 1 mg